// Chiranjib Chakraborty 1, 2, * , Ashish Ranjan Sharma 1, * , Garima Sharma 1 , Bimal Kumar Sarkar 3 and Sang-Soo Lee 1 1 Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Republic of Korea 2 Department of Bioinformatics, School of Computer Sciences, Galgotias University, Greater Noida 203201, Uttar Pradesh, India 3 Department of Physics, School of Basic and Applied Science, Galgotias University, Greater Noida 203201, Uttar Pradesh, India * These authors contributed equally to this work Correspondence to: Chiranjib Chakraborty, email: drchiranjib@yahoo.com Sang-Soo Lee, email: totalhip@hallym.ac.kr Keywords: miRNA; combination therapy; chemotherapeutic agents; cancer; next-generation therapy Received: September 13, 2017 Accepted: December 11, 2017 Published: January 23, 2018 ABSTRACT Medical practitioners are recommending combination therapy in cancer for its various advantages. Combination therapy increases the efficacy of treatment due to its synergistic effects in cancer treatment. In this post-genomic era, microRNAs (miRNAs) are receiving attention for their role in human disease and disease therapy. In this review, we discuss the combination of miRNAs and chemotherapeutic agents for cancer treatment. Moreover, we attempted to portray the role of miRNAs in cancer therapy; outline combination therapy, especially chemo-combination therapy, and discuss the basis for miRNA-based chemo-combination therapies and chemo-combination therapy with miRNA for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: